Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
Hollak
C E M
CE
Department of Internal Medicine/Endocrinology and Metabolism, Academic Medical Center, G4-211, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. c.e.hollak@amc.uva.nl
Linthorst
G E
GE
D000795:Fabry Disease / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology*; D006801:Humans; D007527:Isoenzymes / Q000276:immunology / Q000627:therapeutic use*; D016896:Treatment Outcome; D000519:alpha-Galactosidase / Q000276:immunology / Q000627:therapeutic use*
D007527:Isoenzymes; D000519:alpha-Galactosidase; C459420:agalsidase beta